Sabatolimab
- Generic Name
- Sabatolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2252262-24-9
- Unique Ingredient Identifier
- 3L7R886Y06
- Background
Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05367401
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05201066
- Locations
- πΊπΈ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈUni of Massachusetts Medical Center, Worcester, Massachusetts, United States
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04812548
- Locations
- πͺπΈ
Novartis Investigative Site, Barcelona, Catalunya, Spain
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04623216
- Locations
- πͺπΈ
Novartis Investigative Site, Barcelona, Catalunya, Spain
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
- Conditions
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 530
- Registration Number
- NCT04266301
- Locations
- πΊπΈ
University Of Miami, Miami, Florida, United States
πΊπΈNorthwestern University, Chicago, Illinois, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.